Abstract Number: 2011 • ACR Convergence 2020
Olokizumab Improves Patient Reported Outcomes in Patients with Moderately to Severely Active Rheumatoid Arthritis Inadequately Controlled by Methotrexate: Results from the Double-Blind, Randomized Controlled Phase III Study
Background/Purpose: We previously reported positive efficacy and safety results of olokizumab (OKZ), an interleukin-6-inhibitor, in patients with RA inadequately controlled by MTX (NCT02760368; CREDO-1) [Nasonov…Abstract Number: 0151 • ACR Convergence 2020
More Than Half of Newly Diagnosed RA Patients Are Not Convinced of the Necessity of RA Medicines: Associations with RA Characteristics, Symptoms, and Function in the Canadian Early Arthritis Cohort (CATCH)
Background/Purpose: Although DMARDs are essential for early aggressive control of RA to reduce symptoms and disability, medication adherence is variable. Beliefs about the necessity of…Abstract Number: 0725 • ACR Convergence 2020
A Data Science Evaluation of the Juvenile Arthritis Multidimensional Assessment Report (JAMAR) Questionnaire for Improving Management of JIA Patients
Background/Purpose: The Juvenile Arthritis Multidimensional Assessment Report (JAMAR) is a questionnaire developed to comprehensively assess Juvenile Idiopathic Arthritis (JIA) patients. Despite being translated into 54…Abstract Number: 1273 • ACR Convergence 2020
The Impact of the COVID-19 Pandemic on the Fibromyalgia Symptoms of SLE Patients
Background/Purpose: Many patients with SLE experience symptoms of chronic pain and fatigue, often meeting criteria for fibromyalgia (FM). In this study, we sought to examine…Abstract Number: 0156 • ACR Convergence 2020
The Role of Biological Treatment in the Health-Related Quality of Life of Ankylosing Spondylitis Patients’ Assessment – Meta-Analysis
Background/Purpose: Spondyloarthritis (SpA) is a chronic inflammatory rheumatic disease involving the axial skeleton, entheses and peripheral joints, and may occur together with extra-articular manifestations, such…Abstract Number: 0877 • ACR Convergence 2020
Improvements in Global Functioning and Health-related Quality of Life and Their Association with Disease Activity and Functional Improvement in Patients with Active Ankylosing Spondylitis Treated with Upadacitinib
Background/Purpose: Upadacitinib (UPA) has been shown to be effective and well tolerated in patients with active ankylosing spondylitis (AS) [1]. However, improvements in global functioning…Abstract Number: 1284 • ACR Convergence 2020
Application of a Novel Method for Determination of Muscle Mass Relative to Fat Mass in Women with Systemic Lupus Erythematosus and Association with Disability
Background/Purpose: Patients with SLE are at risk for both skeletal muscle loss and increased adiposity, which may predispose to worse health-related quality of life. Decreased…Abstract Number: 0166 • ACR Convergence 2020
Prevalence and Impact of Unacceptable Symptom State Among Patients with Psoriatic Arthritis: Results from the National Psoriasis Foundation’s 2019 Annual Survey
Background/Purpose: Despite many efficacious therapies for PsA, many patients do not achieve remission. Ongoing disease activity leads to many downstream effects including diminished functional ability,…Abstract Number: 0900 • ACR Convergence 2020
Achievement of Low Disease Activity According to BASDAI with Ixekizumab in Patients with Axial Spondyloarthritis: 16-Week Results from the COAST Trials
Background/Purpose: The efficacy of ixekizumab (IXE), a selective interleukin-17A antagonist, was assessed in patients (pts) with axial SpA (axSpA) in three Phase 3, randomized, double-blind,…Abstract Number: 1285 • ACR Convergence 2020
Association of Frailty with Disability Is Not Attenuated by Lean Body Mass in Women with SLE
Background/Purpose: Frailty has been associated with disability and mortality in SLE. Whether this association is confounded by sarcopenia, a degenerative loss of muscle mass and…Abstract Number: 0167 • ACR Convergence 2020
Rheumatoid Arthritis Patient Phenotypes from a Digital Health Coaching Engagement Program
Background/Purpose: The goal of this study was to examine whether cluster analysis could be used to identify homogeneous subgroups of engagement in RA patients enrolled…Abstract Number: 0919 • ACR Convergence 2020
Determinants of Health-related Quality of Life in Systemic Sclerosis
Background/Purpose: Systemic Sclerosis (SSc) is a heterogeneous disease, in which multiple manifestations are associated with considerable morbidity and mortality. Cross sectional studies have shown that…Abstract Number: 1314 • ACR Convergence 2020
Fatigue in Psoriatic Arthritis (PsA): Prevalence in Patients from the US and Europe, and Impact on Quality of Life and Work Productivity
Background/Purpose: Fatigue is an important aspect of PsA for patients. Understanding the impact of fatigue on patient reported outcomes is important for effective management of…Abstract Number: 0168 • ACR Convergence 2020
Impact of Adalimumab (Humira) Therapy on Ocular Inflammation, Selected Health Care Resource Utilization, and Patient-Reported Outcomes in Patients with Active Non-infectious Intermediate, Posterior, or Panuveitis in Routine Clinical Practice
Background/Purpose: VISUAL clinical trials demonstrated efficacy and safety of adalimumab (ADA) in patients with active and inactive non-infectious, intermediate, posterior, or panuveitis (NIIPPU).1-3 The purpose…Abstract Number: 0930 • ACR Convergence 2020
Sexual Health Impairment in 90 Female Patients with Systemic Sclerosis
Background/Purpose: Systemic sclerosis (SSc) is a chronic, multisystem, connective tissue disorder characterized by fibrosis of the skin and internal organ involvement. These serious clinical manifestations…
- « Previous Page
- 1
- …
- 22
- 23
- 24
- 25
- 26
- …
- 30
- Next Page »